

1. Record Nr.	UNINA9910825074903321
Titolo	Aggressive breast cancer [[electronic resource] /] / Regina H. DeFrina, editor
Pubbl/distr/stampa	New York, : Nova Science Publishers, c2010
ISBN	1-61761-864-0
Descrizione fisica	1 online resource (276 p.)
Collana	Cancer etiology, diagnosis and treatments series
Altri autori (Persone)	DeFrinaRegina H
Disciplina	616.99/449
Soggetti	Breast - Cancer Breast - Diseases
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	<p>""AGGRESSIVE BREAST CANCER ""; ""AGGRESSIVE BREAST CANCER ""; ""CONTENTS ""; ""PREFACE""; ""RESEARCH AND REVIEW ARTICLES""; ""THE HER2 ONCOGENE IN BREAST CANCER ""; ""ABSTRACT ""; ""INTRODUCTION ""; ""HER PROTEIN RECEPTORS: SIGNAL TRANSDUCTION AND ONCOGENESIS ""; ""Intracellular Signaling Pathways ""; ""HER-Induced Cell Cycle Progression and Survival Pathways ""; ""OVER EXPRESSION OF HER2 AND THE PROGNOSIS OF INVASIVE BREAST CANCER ""; ""HER2 as A Prognostic Factor: Node-Positive Versus Node-Negative Disease""; ""HER Status and Lymphoid Infiltration ""</p> <p>""HER2 and Progression of Early Breast Cancer Lesions to Invasive Carcinomas""""Relationship Between HER2 and Estrogen Receptor Expression ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""HER2 ABNORMALITIES IN OTHER TYPES OF BREAST MALIGNANCIES ""; ""Evaluating HER2 in Breast Tissue ""; ""HER2 TARGETED THERAPY IN BREAST CANCER ""; ""The Role of Trastuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Pertuzumab in HER2 Overexpressing Breast Cancer ""; ""The Role of Trastuzumab-DM1 in HER2 Overexpressing Breast Cancer ""</p> <p>""Inhibiting Several HER Receptors: The Role of Lapatinib in HER2 Overexpressing Breast Cancer """"Circulating Serum HER2 Levels ""; ""PROPOSED RESISTANCE TO ANTI-HER2 THERAPIES ""; ""Altered Receptor-Antibody Interaction ""; ""Increased Signaling from other</p>

Receptors of the HER Family"; "Increased Signaling from other Receptors Activating the MAPK and PI3K Pathways"; "Constitutive Activation of Downstream Effectors"; "HER2 OVEREXPRESSION AND CHEMOTHERAPY"; "Anthracyclines"; "Taxanes"; "HER2 OVEREXPRESSION AND HORMONAL THERAPY"; "CNS DISEASE IN HER2 OVEREXPRESSED BREAST CANCER"; "CNS Metastases in Adjuvant Trials of Trastuzumab"; "Prognosis of CNS Metastases in HER2 Overexpressing Breast Cancer"; "CONCLUSION"; "REFERENCES"; "MULTI-DRUG RESISTANCE AS A PROBLEM CHALLENGING BREAST CANCER CHEMOTHERAPY"; "ABSTRACT"; "INTRODUCTION"; "1) Non-Cellular MDR Mechanisms"; "2) Cellular MDR Mechanisms: "; "1. Changes in the intracellular accumulation and distribution of the drug"; "1a. Alteration of drug influx"; "1b. Alteration of drug efflux"; "NORMAL TISSUE DISTRIBUTION"; "PHYSIOLOGICAL FUNCTIONS OF P-GP"; "PHARMACOLOGICAL FUNCTIONS OF P-GP"; "P-GP SUBSTRATES"; "2. Increase in Drug Detoxification"; "3. Alterations of Drug Targets"; "4. Increase in DNA Repair Mechanism"; "5. Changes in Key Genes Controlling Cell Proliferation"; "5a. Changes in genes responsible for cell cycle control"; "5b. Abrogation of apoptosis"; "6. Micro-Environmental Stress-Mediated Resistance of Solid Tumors"; "7. Cancer Cell Dormancy and Resistant Cancer Stem Cells"; "MODULATION OF MDR PHENOTYPE"; "I. Circumvention of Drug Resistance Induced by P-Gp Pump Protein";
